ESMO - Eur. Oncology· @myESMO · X·· 14 小时前评分70
正文 · 原文
#ESMO26: Significant improvements in overall survival in the DeLLphi-305 #ClinicalTrial with the bispecific T-cell engager #immunotherapy tarlatamab added to durvalumab could be practice-changing in extensive-stage #SCLC
🔗 https://ow.ly/6HyL50ZZlne
#InsightsbyESMO #LungCancer
401 浏览 · 3 赞 · 2 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：ESMO - Eur. Oncology · x.com